TrialPloS one2023

Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.

Daniel Bradshaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.